Synonyms: ACTR-IIB, Activin receptor type-2B
Bimagrumab (Anti-ACVR2B) is a human monoclonal antibody targeting activin type II receptor (ActRII). It can be used for the treatment of pathological muscle loss and weakness. MW : 150 KD.
Shimon Sakaguchi
Nature Communications 2025,16, Article number:1325
David Baker
Dev Cell 2023, 58(20):2163-2180.e9.
David Julius
Cell 2017, 185-198.e16
Michael Houghton
Cell Chem Biol, 2020, 27(7):780-792.e5
Charles M. Rice
Cell 2018, 172(3):423-438.e25
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Bimagrumab (Anti-ACVR2B) is a human monoclonal antibody targeting activin type II receptor (ActRII). It can be used for the treatment of pathological muscle loss and weakness. MW : 150 KD.
|
|---|
| CAS No. | 1356922-05-8 |
|---|---|
| Molecular Weight | 150 kDa |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT05933499 | RECRUITING | Drug: Bimagrumab|Drug: Tirzepatide | Obesity | Massachusetts General Hospital | 2025-11-05 | PHASE2 |
| NCT06643728 | ACTIVE_NOT_RECRUITING | Drug: Bimagrumab|Drug: Tirzepatide|Drug: Bimagrumab Placebo| | Obesity; Overweight | Eli Lilly and Company | 2024-10-21 | PHASE2 |
| NCT06890611 | COMPLETED | Drug: Bimagrumab|Drug: Tirzepatide|Drug: Bimagrumab + Tirzep | Healthy | Eli Lilly and Company | 2025-03-25 | PHASE1 |
| NCT06901349 | WITHDRAWN | Drug: Bimagrumab|Drug: Tirzepatide|Drug: Bimagrumab Placebo| | Obesity; Overweight | Eli Lilly and Company | 2025-05-23 | PHASE2 |
| NCT05616013 | COMPLETED | Drug: Semaglutide | Obesity; Obese; Overweight or Obesity | Eli Lilly and Company | 2022-11-16 | PHASE2 |
| NCT03005288 | COMPLETED | Drug: BYM338 10 mg/kg | Diabetes Mellitus, Type 2 | Novartis Pharmaceuticals | 2017-02-01 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-03-27)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.